Alcon Stock Forecast, Price & News

Alcon (NYSE:ALC) Frequently Asked Questions

Is Alcon a buy right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alcon in the last twelve months. There are currently 7 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Alcon stock.
View analyst ratings for Alcon or view top-rated stocks.

How has Alcon's stock price been impacted by COVID-19?

Alcon's stock was trading at $54.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ALC shares have increased by 43.7% and is now trading at $77.91.
View which stocks have been most impacted by COVID-19.

When is Alcon's next earnings date?

Alcon is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Alcon.

How were Alcon's earnings last quarter?

Alcon Inc. (NYSE:ALC) announced its quarterly earnings results on Monday, November, 8th. The healthcare company reported $0.54 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.50 by $0.04. The healthcare company had revenue of $2.08 billion for the quarter, compared to analysts' expectations of $2.04 billion. Alcon had a trailing twelve-month return on equity of 5.22% and a net margin of 4.11%.
View Alcon's earnings history.

How often does Alcon pay dividends? What is the dividend yield for Alcon?

Alcon announced a -- dividend on Monday, May 3rd. Investors of record on Wednesday, May 5th will be paid a dividend of $0.1103 per share on Thursday, May 6th. This represents a yield of 0.15%. The ex-dividend date is Tuesday, May 4th.
View Alcon's dividend history.

What price target have analysts set for ALC?

14 brokers have issued 1 year target prices for Alcon's stock. Their forecasts range from $74.00 to $95.00. On average, they expect Alcon's share price to reach $85.70 in the next year. This suggests a possible upside of 10.0% from the stock's current price.
View analysts' price targets for Alcon or view top-rated stocks among Wall Street analysts.

Who are Alcon's key executives?

Alcon's management team includes the following people:

• David J. Endicott, Chief Executive Officer & Director
• Timothy C. Stonesifer, Chief Financial Officer & Senior Vice President
• Franck Leveiller, Head-Global Research & Development
• Sue-Jean Lin, Chief Information Officer & Senior Vice President
• Royce R. Bedward, Secretary, Senior Vice President & General Counsel

What is Greg D. Wight's approval rating as Alcon's CEO?

6 employees have rated Alcon CEO Greg D. Wight on Glassdoor.com. Greg D. Wight has an approval rating of 100% among Alcon's employees. This puts Greg D. Wight in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Alcon's key competitors?

Some companies that are related to Alcon include HCA Healthcare (HCA), Universal Health Services (UHS), Tenet Healthcare (THC), Encompass Health (EHC), Acadia Healthcare (ACHC), The Ensign Group (ENSG), Petco Health and Wellness (WOOF), Select Medical (SEM), Community Health Systems (CYH), U.S. Physical Therapy (USPH), National HealthCare (NHC), Brookdale Senior Living (BKD) and Five Star Senior Living (FVE).
View all of ALC's competitors.

What other stocks do shareholders of Alcon own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Alcon investors own include AT&T (T), Novartis (NVS), Verizon Communications (VZ), International Business Machines (IBM), Intel (INTC), Pfizer (PFE), Cisco Systems (CSCO), Johnson & Johnson (JNJ), Exxon Mobil (XOM) and AbbVie (ABBV).

What is Alcon's stock symbol?

Alcon trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALC."

Who are Alcon's major shareholders?

Alcon's stock is owned by many different institutional and retail investors. Top institutional investors include Capital Investment Services of America Inc. (0.05%), First Fiduciary Investment Counsel Inc. (0.00%), M&G Investment Management Ltd. (0.03%), Chesley Taft & Associates LLC (0.01%), Crossmark Global Holdings Inc. (0.01%) and Gateway Investment Advisers LLC (0.00%).

Which major investors are selling Alcon stock?

ALC stock was sold by a variety of institutional investors in the last quarter, including FNY Investment Advisers LLC, Capital Investment Services of America Inc., M&G Investment Management Ltd., 17 Capital Partners LLC, Fulton Bank N.A., and Wedbush Securities Inc..

Which major investors are buying Alcon stock?

ALC stock was bought by a variety of institutional investors in the last quarter, including Cutler Group LP, First Fiduciary Investment Counsel Inc., Arlington Partners LLC, Spire Wealth Management, Gateway Investment Advisers LLC, Chesley Taft & Associates LLC, Crossmark Global Holdings Inc., and Marotta Asset Management.

How do I buy shares of Alcon?

Shares of ALC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Alcon's stock price today?

One share of ALC stock can currently be purchased for approximately $77.91.

How much money does Alcon make?

Alcon has a market capitalization of $38.04 billion and generates $6.83 billion in revenue each year. The healthcare company earns $-531 million in net income (profit) each year or $0.67 on an earnings per share basis.

How many employees does Alcon have?

Alcon employs 23,655 workers across the globe.

When was Alcon founded?

Alcon was founded in 1945.

What is Alcon's official website?

The official website for Alcon is www.alcon.com.

Where are Alcon's headquarters?

Alcon is headquartered at Rue Louis-d`Affry 6, Fribourg V8, 1701.

How can I contact Alcon?

Alcon's mailing address is Rue Louis-d`Affry 6, Fribourg V8, 1701. The healthcare company can be reached via phone at 41-58-911-2000, via email at [email protected], or via fax at 41-58-911-3222.